A room in an Italian RSA is not a workable placement if a time-sensitive biologic medicine cannot follow the resident. Families arranging care from abroad should confirm four connected systems before accepting a place: prescribing authority, SSN supply, refrigerated transport and storage, and administration on the scheduled date.
AIFA explains that biologic medicines include complex products such as hormones, enzymes, immunoglobulins and monoclonal antibodies. Its monitoring platform lists active registries and therapeutic plans; the active list was updated on 19 August 2026. AIFA also advises checking each medicine’s leaflet for storage conditions and notes that medicines requiring cold conditions need controlled transport. Those national rules do not tell you whether a particular RSA can receive, store and administer your relative’s product.
Identify the exact access route before comparing homes
Ask the current specialist for the medicine’s brand and active ingredient, indication, dose, interval, next due date, therapeutic-plan expiry and dispensing route. Record whether supply comes from a hospital pharmacy, local health authority or community pharmacy.
Do not treat “biologic treatment” as one category. An injection every several months creates a different placement problem from a weekly dose, an infusion or a medicine tied to an AIFA registry. The RSA needs the exact route to assess admission.
Check who can renew the therapeutic plan
Some medicines require a specialist plan or registry-based monitoring for SSN reimbursement. Ask which authorised centre can issue or renew it after the move and whether the current centre remains responsible. If the resident changes region, verify recognition and the next appointment before the old plan expires.
Put the renewal date on the admission timeline. A home may be clinically willing to help but unable to obtain the medicine if the prescribing paperwork lapses. Ask whether the RSA doctor coordinates with the specialist or whether the family must book and transport the resident.
Map the medicine from pharmacy to fridge
Request a written chain of custody. Who orders the dose, collects or receives it, checks the package, records the temperature and places it in secure refrigeration? Ask whether delivery can go directly to the RSA and who is authorised to sign.
If relatives collect the medicine, obtain the pharmacy’s transport instructions and use appropriate packaging. A household cool bag is not automatically a validated solution. Keep the handover time short and record what the RSA will accept.
Inspect storage rather than accepting “we have a fridge”
Ask whether medicines are stored in a dedicated, monitored refrigerator with restricted access. Confirm the permitted temperature range from the leaflet, how readings are recorded and what happens after an excursion or power failure. The RSA should contact the pharmacy or prescriber rather than guess whether a dose remains usable.
Clarify space and labelling, particularly when a large package or multiple prefilled devices arrive together. Personal food refrigeration and an unmonitored staff fridge are warning signs.
Confirm who administers the dose
State the route and timing. Ask which professional gives the injection, whether competency or specialist supervision is required, and whether the service is available on evenings, weekends and holidays. If administration must occur at a hospital clinic, price the journey and escort.
The answer should distinguish routine nursing work, an external service and a hospital-only procedure. Obtain a plan for the first dose after admission. A general promise to “manage medicines” does not settle these questions.
Calculate the full treatment-related cost
Separate the medicine price from administration, specialist visits, laboratory monitoring, transport, escort time, cold-chain delivery and privately purchased consumables. For an SSN-supplied medicine, ask what proof of eligibility and exemption is needed; do not assume every associated service is free.
Request a sample invoice or tariff schedule from the RSA. Identify which items are included in the accommodation fee and which can be charged separately. If the medicine is temporarily unavailable through the usual route, do not authorise a private purchase without a written price and clinical approval.
Plan laboratory and safety monitoring
Biologic treatments may require tests or specialist review. Ask the prescriber for the individual schedule and warning signs. Then test the RSA’s logistics: can blood be taken on site, who sees results, and who pauses or reschedules treatment when instructed?
Avoid generic disease advice. The home needs a resident-specific instruction sheet and current contacts. Families should know who calls them, but clinical decisions remain with authorised professionals.
Prepare for delayed, missed or damaged doses
Ask the specialist what the RSA should do if a delivery is late, a fridge alarm occurs or the resident is in hospital on the due date. Do not improvise timing or double a dose. Record the contact path for office hours and urgent advice.
Maintain a small administrative reserve: prescription copies, plan details, dispensing contacts and delivery references. Do not build a stock beyond authorised quantities simply to reduce anxiety.
Make the admission handover auditable
Before moving day, send the RSA a one-page summary and obtain confirmation from its clinical lead. On arrival, reconcile the medicine, quantity, batch where relevant, expiry and storage instruction. Both parties should sign the handover record.
Schedule the first specialist review and next order immediately. For an overseas family, appoint a local contact or formal representative who can receive notices without displacing the RSA’s duties.
Compare RSAs using one treatment scenario
Score each option on therapeutic-plan coordination, pharmacy relationship, delivery acceptance, monitored refrigeration, administration competency, laboratory access, transport and transparent extras. Use the same next-dose date and support needs for every home.
A lower daily fee may be outweighed by private escorts or external nursing. A home with a clear chain of custody can be more reliable even if its headline price is higher.
Ask about commissions and commercial links
Ask a placement service whether the RSA pays it a commission and whether non-paying homes were considered. Ask the RSA whether its suggested pharmacy or transport provider is commercially connected and whether alternatives are allowed.
Commercial links do not prove poor care, but they can shape recommendations and prices. Verify reimbursement with the competent health authority and the clinical plan with the specialist.
How Curalune can support the decision
Curalune can select options using the resident’s treatment route, timing, monitoring needs and cost risks. Through the fuller contact service, Curalune can ask shortlisted Italian RSAs the same operational questions, check current availability and organise the replies for an overseas family.
Curalune does not guarantee availability, reservation, SSN coverage, clinical acceptance or admission. Those decisions remain with the RSA, health authorities, pharmacies and treating professionals.
Frequently asked questions
Can an Italian RSA receive a refrigerated biologic directly?
Some can, but delivery authority, handover, monitored storage and responsibility must be confirmed with the RSA and dispensing service.
Does an AIFA therapeutic plan continue after a regional move?
Do not assume so. Ask the authorised centre and destination health authority how renewal and supply will work before the current plan expires.
Is administration included in the RSA fee?
It depends on the contract, route and staffing. Request a written breakdown for administration, external visits, transport and monitoring.
Does Curalune guarantee that an RSA will accept the treatment?
No. Curalune can compare options and obtain information, but the RSA and responsible clinicians decide whether admission and treatment are feasible.